Rubicon Research Ltd
Rubicon Research Ltd (RUBICON) last reported results for the quarter ended Jun 2026, with sales of ₹534 crore and net profit of ₹85 crore. The stock last traded at ₹1,604, a market capitalisation of ₹26,546 crore, on a P/E of 92.1. Over the past 52 weeks the stock has ranged between ₹571 and ₹1,899. Figures are as of 6 Oct 2026 and are not real time.
Rubicon Research Ltd share price and key metrics
- Current price
- ₹1,604
- Market cap
- ₹26,546 cr
- Stock P/E
- 92.1
- Book value
- ₹78.1
- ROE
- 27.0%
- ROCE
- 28.4%
- Dividend yield
- 0.09%
- 52w high / low
- 1899/571
Metrics as of 6 Oct 2026. Not real time.
Track Rubicon Research Ltd
Cruxal reads every Rubicon Research Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Rubicon Research Ltd growth and returns
- 10 Years
- %
- 5 Years
- 41%
- 3 Years
- 65%
- TTM
- 47%
- 10 Years
- %
- 5 Years
- 52%
- 3 Years
- 155%
- TTM
- 89%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 27%
- Last Year
- 27%
Rubicon Research Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹534 cr, up 51.7% from ₹352 cr a year earlier. Net profit was ₹85 cr, up 97.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 |
| Operating profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | 24% |
| Other income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | 23% |
| Net profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 |
| EPS (₹) | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | 5.13 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Rubicon Research Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 263 | 315 | 314 | 394 | 854 | 1,284 | 1,754 | 1,936 |
| Operating profit | 81 | 92 | -39 | 18 | 155 | 264 | 400 | 450 |
| OPM % | 31% | 29% | -12% | 4.7% | 18% | 21% | 23% | 23% |
| Net profit | 49 | 31 | -67 | -17 | 91 | 134 | 247 | 288 |
| EPS (₹) | 97.46 | 60.53 | -132.39 | -33.31 | 5.98 | 8.72 | 14.95 | 17.69 |
TTM is the trailing twelve months to the most recent quarter.
Rubicon Research Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 15 | 15 | 17 |
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 1,272 |
| Borrowings | 30 | 93 | 175 | 320 | 425 | 418 | 311 |
| Other liabilities | 60 | 71 | 79 | 144 | 300 | 493 | 727 |
| Total liabilities | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 |
| Fixed assets | 157 | 188 | 193 | 199 | 307 | 327 | 532 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 41 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 27 |
| Other assets | 252 | 330 | 364 | 526 | 793 | 1,118 | 1,728 |
| Total assets | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 |
As reported by the company. Total assets equal total liabilities by construction.
Rubicon Research Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from investing | -84 | -46 | -46 | -32 | -68 | -65 | -407 |
| Cash from financing | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| Net cash flow | 1 | 67 | -45 | 16 | -4 | 54 | 81 |
| Free cash flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
| CFO / operating profit | 40% | 104% | 138% | -394% | 25% | 75% | 78% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Rubicon Research Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 17% | -12% | 1% | 19% | 26% | 28% |
| Debtor days | 194 | 158 | 162 | 209 | 129 | 92 | 106 |
| Inventory days | 360 | 508 | 502 | 609 | 428 | 574 | 550 |
| Days payable | 183 | 271 | 320 | 353 | 252 | 263 | 285 |
| Cash conversion cycle | 371 | 395 | 345 | 465 | 305 | 403 | 371 |
| Working capital days | 183 | 149 | 107 | 75 | 57 | 46 | 104 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Rubicon Research Ltd shareholding pattern
Promoters held 59.76% at Jun 2026, broadly unchanged since Dec 2025. FIIs 7.52% and DIIs 9.43%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 59.99% | 59.86% | 59.76% |
| FIIs | 7.99% | 7.54% | 7.52% |
| DIIs | 9.45% | 10.02% | 9.43% |
| Public | 22.57% | 22.57% | 23.29% |
| No. of shareholders | 31,914 | 33,738 | 43,254 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Rubicon Research Ltd corporate filings
- SEBI Disclosure: US FDA Inspection of Rubicon Research's Satara FacilityCompany Updatelow impact
Cruxal's analysis: Rubicon Research Ltd has disclosed a US FDA inspection of its manufacturing facility in…
Read the full analysis - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- Rubicon Research Ltd announces allotment of ESOPs under Regulation 30, no immediate financial impactCompany Updatelow impact
Cruxal's analysis: On October 8, 2026, Rubicon Research Ltd disclosed the allotment of Employee Stock Option…
Read the full analysis - Intimation of Trading Window ClosureInsider Trading / SASTlow impact
- General Atlantic Sells 1.40 Crore Shares of Rubicon Research via Open MarketInsider Trading / SASThigh impact
Cruxal's analysis: Rubicon Research Limited has disclosed that its promoter, General Atlantic Singapore RR…
Read the full analysis - General Atlantic Singapore RR Pte. Ltd. reduces stake in Rubicon Research Limited via open market saleInsider Trading / SASThigh impact
Cruxal's analysis: Rubicon Research Limited has witnessed a significant stake sale by its promoter entity…
Read the full analysis - Rubicon Research Limited shareholders approve merger of subsidiary KIA Health Tech and new ESOP 2026 plan at 27th AGMAGM/EGMmedium impact
Cruxal's analysis: Rubicon Research Limited has successfully concluded its 27th Annual General Meeting, with…
Read the full analysis - Rubicon Research Limited concludes 27th AGM; highlights strong FY26 financial growth and strategic expansionAGM/EGMhigh impact
Cruxal's analysis: Rubicon Research Limited successfully concluded its 27th Annual General Meeting, where…
Read the full analysis - Rubicon Research Reports Strong Q1 FY27 Results with 51% Revenue Growth and Upward EBITDA Margin GuidanceCompany Updatehigh impact
Cruxal's analysis: Rubicon Research Limited delivered a robust Q1 FY27 performance, reporting revenue of 534…
Read the full analysis - Rubicon Research Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Rubicon Research Ltd has completed the mandatory newspaper publication of its financial…
Read the full analysis - Rubicon Research Limited releases audio recording of Q1 FY2027 earnings conference callCompany Updatelow impact
Cruxal's analysis: Rubicon Research Limited has formally disclosed the audio recording of its earnings…
Read the full analysis - Rubicon Research Ltd releases Monitoring Agency Report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Rubicon Research Ltd has filed its Monitoring Agency Report for the quarter ended June…
Read the full analysis - Rubicon Research Announces CFO Leadership Transition and Extension of Chairman's TenureCompany Updatelow impact
Cruxal's analysis: Rubicon Research Limited has announced a strategic leadership transition, appointing Mr…
Read the full analysis - Rubicon Research Reports Strong Q1 FY27 Growth with 51.6% Revenue Surge and Upward EBITDA Margin GuidanceCompany Updatehigh impact
Cruxal's analysis: Rubicon Research Limited delivered robust Q1 FY27 results, reporting revenue from…
Read the full analysis - Rubicon Research Reports Strong Q1 FY27 Performance with Consolidated Revenue of 534.34 crore and PAT of 84.78 croreBoard Meetinghigh impact
Cruxal's analysis: Rubicon Research Limited delivered a robust performance for the quarter ended June 30…
Read the full analysis - Rubicon Research Ltd issues corrigendum to FY 2025-26 Integrated Annual ReportOtherslow impact
Cruxal's analysis: Rubicon Research has filed a corrigendum regarding its Integrated Annual Report for the…
Read the full analysis - Rubicon Research Ltd announces 27th Annual General Meeting and releases Integrated Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Rubicon Research Ltd has filed its notice for the 27th Annual General Meeting along with…
Read the full analysis - Rubicon Research Schedules Q1 FY27 Earnings Conference Call for August 14, 2026Company Updatelow impact
Cruxal's analysis: Rubicon Research Limited has announced an earnings conference call scheduled for August…
Read the full analysis - Rubicon Research Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Rubicon Research Limited has formally intimated the stock exchanges regarding a Board of…
Read the full analysis - Rubicon Research Ltd publishes newspaper advertisement for 27th Annual General Meeting notice and voting informationCompany Updatelow impact
Cruxal's analysis: Rubicon Research Ltd has announced the newspaper publication of the notice for its 27th…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.